Horizon is a global biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our portfolio, along with our pipeline, is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We are relentless in pursuing breakthroughs that boldly change the lives of the communities we serve. Discover more about our medicines in rheumatology, including the first and only biologic treatment for uncontrolled gout, and research for new therapeutic targets in gout and systemic sclerosis at www.HorizonTherapeutics.com.
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make a global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue asset-centric global collaborations including strategic investments.
Arthrosi Therapeutics, Inc., founded in San Diego, CA in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage, while improving quality of life for people living with gout. With its extensive therapeutic and treatment knowledge, Arthrosi has developed an industry leading, safe, and potent selective URAT1 inhibitor that has completed Phase 1, Phase 2a and 2b studies, and currently enrolling a Phase 2 (clinically) tophaceous gout study.
